Aravive Announces Board Composition and Executive Management Transitions
April 09, 2020 07:08 ET
|
Aravive, Inc.
Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre, Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM ET ...
Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
March 30, 2020 08:00 ET
|
Aravive, Inc.
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates
March 27, 2020 08:00 ET
|
Aravive, Inc.
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020Company announces clinical trial updates for clear cell...
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
March 24, 2020 08:00 ET
|
Aravive, Inc.
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
Aravive To Present at The Cowen and Company 40th Annual Health Care Conference
February 25, 2020 16:07 ET
|
Aravive, Inc.
HOUSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will present at Cowen and Company's 40th Annual Health...
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
February 18, 2020 08:00 ET
|
Aravive, Inc.
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
Aravive Receives IND Clearance for Phase 1b/Phase 2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
January 13, 2020 08:00 ET
|
Aravive, Inc.
HOUSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
Aravive Announces Management Changes
January 09, 2020 16:05 ET
|
Aravive, Inc.
Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline Jay Shepard to Assume Role of Chairman of the Board of...
Aravive Initiates a Phase 2a Clinical Trial of AVB-500 in Patients with Kidney Fibrosis
December 20, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a...
Aravive Announces Participation at the 2019 Piper Jaffray Healthcare Conference
December 02, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...